PDLIM7 and lymphoma: We postulated that bort/venetoclax might have a wider clinical application for other EBV-associated lymphoma dependent on LMP-1, EBNA-3C or BHRF-1 for survival function and be particularly beneficial to patients with immunodeficiency-associated lymphoma or lymphoma associated with aging such as EBV-positive diffuse large B cell lymphoma.